BioStem Technologies (OTC: BSEM) reported a resilient Q3 2025, generating $10.5 million in net revenue, $0.8 million in GAAP net income, and achieving its seventh consecutive quarter of positive adjusted EBITDA, coming in at $2.7 million.
Despite modest pricing-related revenue pressure, the company continues to demonstrate financial strength, supported by an 88.5% gross margin and a $27.2 million cash balance. Zacks Small Cap Research maintains a $25.50 price target, reflecting confidence in BioStem's operational performance, expanding revenue channels, and maturing clinical portfolio.
With new penetration into VA and Medicaid programs, growing hospital and ASC opportunities, and a Nasdaq uplisting targeted for mid-2026, BioStem is positioning itself for long-term growth in a MedTech market that continues to benefit from strong demand, aging demographics, and underpenetrated regenerative-care needs.
Has BA Stock Reached the "So Bad, It's Good" Stage?
Posted On Dec 08, 2025 by Chris Markoch
Shares of Boeing Co. (NYSE: BA) have made a strong recovery with the broader market under pressure. BA stock is up 5.6% in the 30 days ending December 5 and has broken out of a pronounced three-month downtrend.
Table of Contents
That can be a bullish signal as investors may be looking for undervalued opportunities in areas outside of the tech sector. However, while there may be reasons to buy into the long-term story for Boeing, it's fair to ask whether now is the time to for investors to jump on board.
Bullish Signal: The Acquisition of Spirt AeroSystems is Complete
The acquisition does several things for Boeing. Primary among them, it brings "all of Spirit’s Boeing-related commercial operations, including fuselages for the 737 program and major structures for the 767, 777 and 787 Dreamliner" in-house. This also includes Spirit's commercially procured fuselages for the P-8 and KC-46.
Spirit was also Boeing's largest supplier of spare parts, which now is brought under the Boeing umbrella. This will also be a boost to the company's global maintenance, repair, and overhaul business.
Bullish Signal: Boeing Receives Regulatory Approval to Increase Production
To take the acquisition of Spirit AeroSystems one step further, the company recently received regulatory approval to increase deliveries. Boeing has a reported backlog of 5,900 commercial airplanes valued at around $636 billion.
Keep in mind that Boeing and Airbus make up a duopoly in the aerospace industry. That's an attractive position for long-term investors looking for certainty of future revenue. However, the regulatory environment has been a constraint.
Boeing has to prove it can successfully ramp up production. This has been a problem for Boeing in the past. That's another reason why the Spirit acquisition may be a bullish signal. It has the potential to remove several links from the supply chain bottleneck.
Bearish Signal: Net Income Remains Negative
There are reasons why BA stock has delivered a negative total return of 15.2% in the last five years. And not all of them have to do with factors outside its control, such as a global pandemic.
The company's quality standards have come under scrutiny, particularly as it relates to its 737 MAX crisis, its 787 and 777X planes as well as fixed price defense contracts that have been loss leaders.
That said, the company's topline revenue has made significant strides in 2025. In its third-quarter earnings report, Boeing reported a 30% year-over-year (YoY) increase on the top line. And it narrowed its net loss by nearly the same percentage.
But narrowing a loss is not the same as turning a profit. To be fair, Boeing took a $4.9 billion pre-tax charge after it delayed the first delivery of its new 777-9 jet to 2027. Without that charge, analysts were forecasting a breakeven or much narrower miss. That said, Boeing's own estimates don't show sustained profitability until 2027 or later.
BA Stock: Upside Seems Limited; Caution Is the Prudent Play
Analyst sentiment is mixed. Overall, BA stock has a Moderate Buy rating with a consensus price target of $232.09, which would give investors an upside of around 12%. However, the spread between analysts' opinions suggests that the stock may be overvalued.
That's supported by the chart action.
BA stock has staged an impressive rebound in December, reclaiming its 50-day simple moving average (SMA) and attempting to hold above the 200-day SMA. This move is technically constructive, but the spread between the two moving averages has compressed. If momentum stalls, there remains a realistic risk of a death cross, where the 50-day breaks below the 200-day—a pattern that can signal extended downside pressure if confirmed.
Price action shows initial resistance near $207 to $210, which aligns with the recent congestion zone prior to the early November breakdown. A sustained breakout above this band could open a path to the next resistance cluster around $220, where Boeing stock failed to hold in September and October. On the downside, first support sits near $200, followed by a stronger level around $188 to $190. This is a level where volume picked up during the late November capitulation.
Momentum indicators are flashing a mixed setup. With RSI near 59, BA is approaching bullish territory without yet being overbought. The MACD remains positive, but the histogram appears to be flattening, hinting at a potential near-term top if buyers don't follow through. The next few sessions will be critical in determining whether BA stock transitions from a bounce to a sustained trend reversal or slips back into consolidation.
This message is a PAID ADVERTISEMENT for BioStem Technologies, Inc (OTC: BSEM) from Sideways Frequency. StockEarnings, Inc. has received a fixed fee of $7000 from Sideways Frequency for multiple Dedicated Email Sends, Newsletter Sponsorships and SMS Sends between December 12, 2025 and December 18, 2025. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either BioStem Technologies, Inc (OTC: BSEM) or Sideways Frequency. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding BioStem Technologies, Inc (OTC: BSEM) on Huge Alerts website for additional information about the relationship between Sideways Frequency and BioStem Technologies, Inc (OTC: BSEM).
Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe.
StockEarnings, Inc 33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA W: 877.6.STOCKS StockEarnings.com
No comments:
Post a Comment